Ultragenyx Agrees To Sell Pediatric Disease Review Voucher For $203 Million In Cash
The drugmaker's 8-K ties the voucher to the FDA's September 17 approval of FAYUVI; a separate report cites $210 million.
Ultragenyx agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in cash, according to an 8-K filed Wednesday. The company signed the asset purchase agreement on October 8.
What the 8-K says
The filing says the buyer will pay the $203 million at closing. It does not name the buyer in the text provided.
The FDA awarded the voucher to Ultragenyx on September 17, 2026, when it approved FAYUVI, also known as UX111, for children with mucopolysaccharidosis type IIIA, or Sanfilippo syndrome Type A.
The agreement carries customary representations, warranties, covenants and indemnification terms, subject to limits. Closing depends on the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the U.S. premerger antitrust review law.
A different figure in another report
A Yahoo Finance report from October 8 described a $210 million voucher sale. It tied the voucher to approval of Genglycos, a different drug, and said 20% of the proceeds is owed to the NIH under a prior patent license.
The 8-K itself says $203 million and links the voucher to FAYUVI, so the two accounts differ. The same report said Ultragenyx shares were down 35.3% year to date.
For holders, the filing's number is the cash the company says it will receive at closing. Shares closed at $14.92 on Tuesday, down 2.48% for the session, before the filing became public Wednesday at 9:00 a.m. ET.
What to watch
The sale closes only once the Hart-Scott-Rodino waiting period ends. The full agreement is to be filed with Ultragenyx's annual report on Form 10-K for the year ended December 31, 2026.
The 10-K for the year ended December 31, 2026 is where the full agreement is due to appear.
Sources
- 8-K Filing — Ultragenyx Pharmaceutical Inc. (RARE) — SEC EDGAR
- Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash — Yahoo Finance
